The invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination to treat and/or prevent cardiac and cardiovascular diseases, renal and cardiorenal diseases, pulmonary and cardiopulmonary disease, and to treat and/or prevent fibrotic diseases.